News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

They help us find better ways to prevent, diagnose, and treat cancer. Nearly all current cancer treatments started in a clinical trial. At any given time, Huntsman Cancer Institute has more than 300 ...

The updated guidelines, consistent with the FDA indication per the NATALEE trial, approximately double the number of patients that could benefit from treatment with a CDK4/6i in the adjuvant setting.

An updated analysis from the NATALEE trial recently presented at the European ... decision within approximately two months. Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

"The Phase III NATALEE trial demonstrated a noteworthy 25.1% ... II and III early breast cancer receiving adjuvant Kisqali (ribociclib) alongside endocrine therapy, compared to those on endocrine ...

consistent with the FDA indication per the NATALEE trial, approximately double the number of patients that could benefit from treatment with a CDK4/6i in the adjuvant setting 3. NCCN Guidelines also ...